Northeast Pharmaceutical Group Management

Management criteria checks 2/4

Northeast Pharmaceutical Group's CEO is Zhou Kai, appointed in May 2019, has a tenure of 3.5 years. directly owns 0.3% of the company’s shares, worth CN¥20.34M. The average tenure of the management team and the board of directors is 2.2 years and 4.5 years respectively.

Key information

Zhou Kai

Chief executive officer

CN¥3.3m

Total compensation

CEO salary percentage	n/a
CEO tenure	5yrs
CEO ownership	0.3%
Management average tenure	2.2yrs
Board average tenure	4.5yrs

Recent management updates

Recent updates

Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Apr 05

CEO

Zhou Kai (59 yo)

5yrs

Tenure

CN¥3,295,500

Compensation

Mr. Zhou Kai serves as a General Manager of Northeast Pharmaceutical Group Co., Ltd. since May 8, 2019 and serves its Non-Independent Director since November 29, 2020. He served as a Vice President of Nort...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Zhou Kai	GM & Director	5yrs	CN¥3.30m	0.30% CN¥ 20.3m
Jialun Song	Financial Director & Secretary	1.3yrs	CN¥337.00k	0.022% CN¥ 1.5m
Wei Zheng	Deputy General Manager	3.2yrs	CN¥652.20k	0.077% CN¥ 5.3m
XiaoFeng Li	Deputy General Manager	less than a year	no data	no data

2.2yrs

Average Tenure

50yo

Average Age

Experienced Management: 000597's management team is considered experienced (2.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Zhou Kai	GM & Director	3.5yrs	CN¥3.30m	0.30% CN¥ 20.3m
Demin Han	Independent Director	5.8yrs	CN¥150.00k	no data
Zhaochun Tan	Non-Independent Director	2.5yrs	no data	no data
Chengren Huang	Non-Independent Director	5.8yrs	no data	0.23% CN¥ 15.5m
Xinhua Ao	Non-Independent Director	5.8yrs	no data	0.23% CN¥ 15.5m
Guodong Wang	Independent Director	5.8yrs	CN¥150.00k	no data
Hui Yao	Independent Director	5.8yrs	CN¥150.00k	no data
Youguang Shang	Independent Director	3.6yrs	CN¥150.00k	no data
Jianmin Guo	Chairman of the Board	2.6yrs	CN¥2.67m	0.22% CN¥ 15.4m
Zhihua Huang	Non-Independent Director	2.5yrs	no data	0.070% CN¥ 4.8m
Baidan Zhan	Chairman of the Supervisory Board	5.4yrs	no data	no data
Hai Tian	Director	less than a year	no data	no data

4.5yrs

Average Tenure

58yo

Average Age

Experienced Board: 000597's board of directors are considered experienced (4.5 years average tenure).

Northeast Pharmaceutical Group Management

Management criteria checks 2/4

Key information

Recent management updates

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 06, 2021

Recent updates

Dividend of CN¥0.10 announced

Northeast Pharmaceutical Group Co., Ltd. Implements 2023 Final Cash Profit Distribution Plan, Payable on 23 May 2024

New minor risk - Earnings quality

First quarter 2024 earnings released: EPS: CN¥0.04 (vs CN¥0.049 in 1Q 2023)

Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Full year 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in FY 2022)

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment deteriorates as stock falls 18%

Northeast Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

High number of new directors

Third quarter 2023 earnings released: EPS: CN¥0.059 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.033 in 2Q 2022)

Now 21% undervalued after recent price drop

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Now 21% undervalued after recent price drop

Northeast Pharmaceutical Group Co., Ltd. Announces 2022 Final Cash Profit Distribution Plan, Payable on 16 May 2023

Full year 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.07 in FY 2021)

Now 21% undervalued

Now 21% undervalued

Now 21% undervalued

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.026 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.033 (vs CN¥0.016 in 2Q 2021)

High number of new directors

Northeast Pharmaceutical Group Co., Ltd. Proposes Final Dividend for the Year 2021, Payable on 27 May 2022

First quarter 2022 earnings released: EPS: CN¥0.051 (vs CN¥0.029 in 1Q 2021)

Northeast Pharmaceutical Group Co., Ltd. Approves the Profit Distribution for 2021

Full year 2021 earnings released: EPS: CN¥0.07 (vs CN¥0.01 in FY 2020)

Northeast Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for 2021

High number of new directors

Third quarter 2021 earnings released: CN¥0.026 loss per share (vs CN¥0.042 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.016 (vs CN¥0.063 in 2Q 2020)

Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend of A Shares, Payable on 27 May 2021

First quarter 2021 earnings released: EPS CN¥0.029 (vs CN¥0.013 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.01 (vs CN¥0.13 in FY 2019)

Northeast Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2020

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 06, 2021

Northeast Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 17, 2021

New 90-day low: CN¥4.86

New 90-day low: CN¥5.03

New 90-day low: CN¥5.37

New 90-day low: CN¥5.39

Third quarter earnings released

Northeast Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Jiangxi Fangda Steel Technology Co., Ltd. completed the acquisition of an additional 10% stake in Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597) for approximately CNY 890 million.

Northeast Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 2 billion in funding from Joyvio Group Co., Ltd., Liaoning Fangda Group Industrial Co., Ltd., and other investors

First half earnings released

New 90-day high - CN¥6.15

New 90-day high - CN¥6.02

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age